Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: Retrospective analysis of an 8 year period

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 488-493

  Chen, Shiuan Chih ^a,b,c,d   Lee, Yuan Ti ^a,b   Tsai, Shih Jei ^a   Chan, Khee Siang ^a,e   Chao, Wai Nang ^e   Wang, Po Hui ^a   Lin, Ding Bang ^a   Chen, Chun Chieh ^a,b   Lee, Meng Chih ^a,b,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f Taichung Hospital   (Taiwan)

Author keywords

Cephalosporins; Fluoroquinolones; Mortality; Treatment effectiveness

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMORBIDITY; DRUG EFFICACY; FATALITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NECROTIZING FASCIITIS; TREATMENT OUTCOME; VIBRIO VULNIFICUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FASCIITIS, NECROTIZING; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 84862929735     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr476     Document Type: Article

References (38)

1. Chuang YC, Young CD, Chen CW. Vibrio vulnificus infection. Scand J Infect Dis 1989; 21: 721-6.
2. Chuang YC, Yuan CY, Liu CY et al. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis 1992; 15: 271-6.
3. Kim HR, Rho HW, Jeong MH et al. Hemolytic mechanism of cytolysin produced from V. vulnificus. Life Sci 1993; 53: 571-7.
4. Biosca EG, Amaro C. Toxic and enzymatic activities of Vibrio vulnificus biotype 2 with respect to host specificity. Appl Environ Microbiol 1996; 62: 2331-7.
5. Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis 1999; 179: 275-8.
6. Powell JL, Strauss KA, Wiley C et al. Inflammatory cytokine response to Vibrio vulnificus elicited by peripheral blood mononuclear cells from chronic alcohol users is associated with biomarkers of cellular oxidative stress. Infect Immun 2003; 71: 4212-6.
7. Chiang SR, Chuang YC. Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 2003; 36: 81-8.
8. Hsueh PR, Lin CY, Tang HJ et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis 2004; 10: 1363-8.
9. Klontz KC, Lieb S, Schreiber M et al. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988; 109: 318-23.
10. Howard RJ, Bennett NT. Infections caused by halophilic marine Vibrio bacteria. Ann Surg 1993; 217: 525-30.
11. Liu JW, Lee IK, Tang HJ et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006; 166: 2117-23.
12. Kuo Chou TN, Chao WN, Yang C et al. Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus. World J Surg 2010; 34: 1669-75.
13. Chen SC, Chan KS, Chao WN et al. Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10-yr retrospective study. Crit Care Med 2010; 38: 1984-90.
14. Howard RJ, Pessa ME, Brennaman BH et al. Necrotizing soft-tissue infections caused by marine Vibrios. Surgery 1985; 98: 126-30.
15. Tsai YH, Hsu RW, Huang TJ et al. Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am 2007; 89: 631-6.
16. Tsai YH, Hsu RW, Huang KC et al. Laboratory indicators for early detection and surgical treatment of Vibrio necrotizing fasciitis. Clin Orthop Relat Res 2010; 468: 2230-7.
17. Park SD, Shon HS, Joh NJ. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J Am Acad Dermatol 1991; 24: 397-403.
18. Bowdre JH, Hull JH, Cocchetto DM. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther 1983; 225: 595-8.
19. Morris JG Jr, Tenney J. Antibiotic therapy for Vibrio vulnificus infection. JAMA 1985; 253: 1121-2.
20. Hsueh PR, Chang JC, Chang SC et al. In vitro antimicrobial susceptibility of Vibrio vulnificus isolated in Taiwan. Eur J Clin Microbiol Infect Dis 1995; 14: 151-3.
21. Chuang YC, Liu JW, Ko WC et al. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 1997; 41: 2214-7.
22. Chuang YC, Ko WC, Wang ST et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998; 42: 1319-22.
23. Tang HJ, Chang MC, Ko WC et al. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 2002; 46: 3580-4.
24. Halow KD, Harner RC, Fontenelle LJ. Primary skin infections secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg 1996; 183: 329-34.
25. Abbott SL, Janda JM, Johnson JA et al. Vibrio and related organisms. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of clinical microbiology. Vol. 1. 9th edn. Washington, DC: ASM Press, 2007; 723-33.
26. Blake PA, Merson MH, Weaver RE et al. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979; 300: 1-5.
27. Johnston JM, Becker SF, McFarland LM. Vibrio vulnificus. Man and the sea. JAMA 1985; 253: 2850-3.
28. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
29. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
30. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Guidelines for intensive care unit admission, discharge, and triage. Crit Care Med 1999; 27: 633-8.
31. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
32. Dofferhoff AS, Esselink MT, de Vries-Hospers HG et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother 1993; 31: 373-84.
33. Prins JM, Kuijper EJ, Mevissen ML et al. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63: 2236-42.
34. Vianna RC, Gomes RN, Bozza FA et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004; 21: 115-20.
35. McConnell JS, Cohen J. Release of endotoxin from Escherichia coli by quinolones. J Antimicrob Chemother 1986; 18: 765-6.
36. Trautmann M, Heinemann M, Möricke A et al. Endotoxin release due to ciprofloxacin measured by three different methods. J Chemother 1999; 11: 248-54.
37. Lepper PM, Held TK, Schneider EM et al. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 2002; 28: 824-33.
38. Chou TN, Lee YT, Lai YY et al. Prognostic factors for primary septicemia and wound infection caused by Vibrio vulnificus. Am J Emerg Med 2010; 28: 424-31.